Stock Taper 
Prestige Consumer Healthcare Inc. develops, markets, and sells OTC health and personal care products globally, including brands like Chloraseptic, Dramamine, and Monistat, through various retail and e-commerce channels.
Launched in February 2026, Prestige Consumer Healthcare's new eye drops offer hydrating relief for eye fatigue and dryness from screen use, reflecting the company's focus on innovative eye care solutions for modern consumers.
In a significant strategic move, Prestige Consumer Healthcare announced the acquisitions of Pillar5 Pharma, a key supplier for its Clear Eyes® brand, and Anjac SAS, a French company that will facilitate entry into the men's health and hydration markets. These acquisitions are aimed at vertically integrating its supply chain to ensure resilience and expanding its product portfolio into high-growth sectors.
In a strategic move to enhance supply chain resilience, Prestige Consumer Healthcare announced the acquisition of Pillar5 Pharma Inc., a leading Canadian sterile ophthalmic manufacturer and a current key supplier for its Clear Eyes® brand. This vertical integration is intended to mitigate supply chain risks and ensure the long-term stability of one of its flagship products.
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
 CON | $36.80 | COMPARE |
 LIVN | $75.82 | COMPARE |
 HTFL | $46.66 | COMPARE |
 ICUI | $156.86 | COMPARE |
 LEGN | $18.58 | COMPARE |
 ZLAB | $24.49 | COMPARE |
 PRVA | $20.40 | COMPARE |
 IRON | $60.02 | COMPARE |
